Exscientia PLC <EXAI.O>: Losses of 38  cents announced for fourth quarter

23 March 2023 01:01 p.m. ​All figures in US dollars. The loss announced by Exscientia PLC in the fourth quarter were lower than the Refinitiv mean estimate of losses. The company reported losses of -

Exscientia PLC reports results for the quarter ended in December - Earnings Summary

* Exscientia PLC reported a quarterly adjusted loss of 38 cents​​ per share for the quarter ended in December. The mean expectation of three analysts for the quarter was for a loss of 32 cents per

Eco Animal Health Says It Sees Revenue and EBITDA Slightly Ahead of Market Expectations for Full Year

March 23 (Reuters) - ECO Animal Health Group PLC : * ECO ANIMAL HEALTH GP - TRADING UPDATE * ECO ANIMAL HEALTH SEES REVENUE AND EARNINGS BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION SLIGHTLY

Amryt Pharma Shareholders Approve Acquisition Of Amryt Pharma By Chiesi Farmaceutici

March 22 (Reuters) - Amryt Pharma PLC * AMRYT PHARMA SHAREHOLDERS APPROVE ACQUISITION OF AMRYT PHARMA BY CHIESI FARMACEUTICI * AMRYT PHARMA PLC - TRANSACTION EXPECTED TO CLOSE IN Q2 2023 Source text

TC Biopharm Announces Corporate Restructuring, Reduction In Overhead

March 22 (Reuters) - Tc Biopharm Ltd: * TC BIOPHARM ANNOUNCES CORPORATE RESTRUCTURING, REDUCTION IN OVERHEAD * COMPANY IS REDUCING ITS WORKFORCE UP TO 30%, WITH MAJORITY OF REDUCTION EXPECTED TO BE

Bookrunner Says Azelis Group NV ABO Price EUR 23.60 Per Share

March 22 (Reuters) - Bookrunner: * AZELIS GROUP NV ABO OFFERING PRICE: EUR 23.60 PER SHARE- BOOKRUNNER Source text for Eikon: Further company coverage:

Hellenic Dynamics Signes MoU With ELGO-DIMITRA

March 22 (Reuters) - Hellenic Dynamics PLC: * HELLENIC DYNAMICS PLC - MEMORANDUM OF UNDERSTANDING WITH ELGO-DIMITRA Source text for Eikon: Further company coverage:

Evgen Pharma Reports Preliminary Pharmacokinetic Results From Phase 1B Study of New SFX-01 Tablet Formulation

March 22 (Reuters) - Evgen Pharma PLC: * EVGEN PHARMA PLC - PRELIMINARY RESULTS FROM PHASE 1B STUDY * EVGEN PHARMA PLC - PRELIMINARY PHARMACOKINETIC RESULTS FROM PHASE 1B STUDY OF NEW SFX-01 TABLET

Sareum Holdings Reports Cash At 31 December 2022 Of £2.9M

March 22 (Reuters) - Sareum Holdings PLC: * SAREUM HOLDINGS PLC - CASH AT 31 DECEMBER 2022 OF £2.9M (£5.6M AS OF 31 DECEMBER 2021 AND £4.3M AS OF 30 JUNE 2022) Source text for Eikon: Further company

Arecor Therapeutics Says First Patient Dosed In AT278 Clinical Trial

March 22 (Reuters) - Arecor Therapeutics PLC: * ARECOR THERAPEUTICS - FIRST PATIENT DOSED IN AT278 CLINICAL TRIAL * ARECOR THERAPEUTICS PLC - TRIAL EXPECTED TO COMPLETE IN Q4 2023 Source text for